Lay media reporting of rosiglitazone risk: Extent, messaging and quality of reporting

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Rabi, Doreen M ^a,b   Lewin, Adriane M ^b   Brown, Garielle E ^a   Edwards, Alun L ^a,b   Johnson, Jeffrey A ^c   Ghali, William A ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ACCESS TO INFORMATION; ACCURACY; CARDIOVASCULAR RISK; CONTENT ANALYSIS; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; EDITORIAL; INFORMATION PROCESSING; LAY MEDIA; MASS COMMUNICATION; MASS MEDIUM; PUBLICATION; REVIEW; RISK ASSESSMENT; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; HUMAN; STANDARD;

CARDIOVASCULAR DISEASES; COMMUNICATIONS MEDIA; HUMANS; NEWSPAPERS; THIAZOLIDINEDIONES;

EID: 68949214466     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-40     Document Type: Review

References (10)

1. Cassels A Hughes MA Cole C Mintzes B Lexchin J McCormack JP Drugs in the news: An analysis of Canadian newspaper coverage of new prescription drugs CMAJ 2003, 168(9):1133-7 153682 12719316
2. Grilli R Ramsay C Minozzi S Mass media interventions: Effects on health services utilisation Cochrane Database Syst Rev 2002, 1:CD000389 11869574
3. Moynihan R Bero L Ross-Degnan D Henry D Lee K Watkins J Mah C Soumerai SB Coverage by the news media of the benefits and risks of medications N Engl J Med 2000, 342(22):1645-50 10.1056/NEJM200006013422206 10833211
4. Woloshin S Schwartz LM Press releases: Translating research into news JAMA 2002, 287(21):2856-8 10.1001/jama.287.21.2856 12038933
5. Cassels A Lexchin J How well do Canadian media outlets convey medical treatment information? Initial findings from a year and a half of media monitoring by Media Doctor Canada Open Medicine 2008, 2(1):E20-E23 Ref Type: Journal (Full)
6. Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007, 356(24):2457-71 10.1056/NEJMoa072761 17517853
7. Levitan D Rosiglitazone: One year later. Endocrine Today 8 A.D. June 25 http://www.endocrinetoday.com/view.aspx?rid=29105
8. Shah BR Juurlink DN Austin PC Mamdani MM New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm Diabet Med 2008, 25(7):871-4 10.1111/j.1464-5491.2008.02462.x 18644075
9. Grey A Bolland M Gamble G Wattie D Horne A Davidson J Reid IR The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial J Clin Endocrinol Metab 2007, 92(4):1305-10 10.1210/jc.2006-2646 17264176
10. Lipscombe LL Gomes T Levesque LE Hux JE Juurlink DN Alter DA Thiazolidinediones and cardiovascular outcomes in older patients with diabetes JAMA 2007, 298(22):2634-43 10.1001/jama.298.22.2634 18073359